PharmaCyte Biotech Net Invested Capital Over Time
| PMCB Stock | USD 1.66 0.04 2.47% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out PharmaCyte Biotech Performance and PharmaCyte Biotech Correlation. PharmaCyte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.64 | Return On Assets (0.05) | Return On Equity 0.4788 |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Invested Capital Analysis
Compare PharmaCyte Biotech and related stocks such as Kezar Life Sciences, Invivyd, and Icosavax Net Invested Capital Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KZR | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | 108.8 M | 78 M | 141 M | 206.5 M | 279.7 M | 197.6 M | 154.9 M |
| IVVD | (65.2 M) | (65.2 M) | (65.2 M) | (65.2 M) | (65.2 M) | (65.2 M) | (65.2 M) | (65.2 M) | (65.2 M) | (65.2 M) | (65.2 M) | 558 M | 356 M | 177.5 M | 282.2 M |
| SPRB | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (26.2 M) | 153.9 M | 116.2 M | 73.4 M | 79.8 M | 69.6 M |
| YMAB | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 140.5 M | 198.9 M | 105.8 M | 180.1 M | 109.2 M | 101 M | 104.9 M |
| STTK | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (34.5 M) | 309.9 M | 271.8 M | 176.2 M | 144.7 M | 157.1 M |
| CSBR | 400 K | 400 K | 400 K | 400 K | 400 K | 400 K | 400 K | 3 K | 2.2 M | 5.3 M | 7.4 M | 9.1 M | 4.6 M | (1.9 M) | (1.8 M) |
| IPSC | (91.9 M) | (91.9 M) | (91.9 M) | (91.9 M) | (91.9 M) | (91.9 M) | (91.9 M) | (91.9 M) | (91.9 M) | (91.9 M) | (96.7 M) | 405.1 M | 313 M | 184.8 M | 157.1 M |
| MOLN | 116.7 M | 116.7 M | 116.7 M | 116.7 M | 116.7 M | 116.7 M | 116.7 M | 116.7 M | 91.7 M | 54.1 M | 107.2 M | 107.3 M | 235.2 M | 176.4 M | 139.6 M |
| MLYS | 903 K | 903 K | 903 K | 903 K | 903 K | 903 K | 903 K | 903 K | 903 K | 903 K | 903 K | (22.9 M) | (52.3 M) | 241.2 M | 253.2 M |
| ANTX | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (47.4 M) | 95.4 M | 124.7 M | 130.9 M |
| PHVS | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 5 M | 18.7 M | 95.8 M | 205 M | 149.3 M | 384 M | 403.3 M |
| PEPG | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (32.1 M) | 179.6 M | 108.4 M | 68.6 M |
| NUVB | 142.2 M | 142.2 M | 142.2 M | 142.2 M | 142.2 M | 142.2 M | 142.2 M | 142.2 M | 142.2 M | 142.2 M | 142.2 M | 746 M | 655.1 M | 605.1 M | 590.8 M |
| OVID | 83.4 M | 83.4 M | 83.4 M | 83.4 M | 83.4 M | 83.4 M | 83.4 M | 83.4 M | 38.8 M | 70 M | 43.6 M | 179.7 M | 132.3 M | 87.8 M | 99.9 M |
| NXTC | (23.6 M) | (23.6 M) | (23.6 M) | (23.6 M) | (23.6 M) | (23.6 M) | (23.6 M) | (23.6 M) | (46.5 M) | 326.5 M | 297.2 M | 233.4 M | 167.5 M | 114.4 M | 168 M |
| CNTB | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (298.3 M) | (1 B) | 1.7 B | 1.1 B | 101 M | 96 M |
| ASMB | 113.1 M | 113.1 M | 113.1 M | 113.1 M | 113.1 M | 113.1 M | 113.1 M | 113.1 M | 210.7 M | 273.2 M | 240.6 M | 168.9 M | 82.7 M | 41.1 M | 39 M |
| TIL | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (39.6 M) | 555.2 M | 436 M | 307.3 M | 275.4 M |
PharmaCyte Biotech and related stocks such as Kezar Life Sciences, Invivyd, and Icosavax Net Invested Capital description
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.My Equities
My Current Equities and Potential Positions
| PharmaCyte Biotech | PMCB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.66
Check out PharmaCyte Biotech Performance and PharmaCyte Biotech Correlation. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
PharmaCyte Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.